
OrsoBio to Present Mitochondrial Protonophore Data at ADA 2026
OrsoBio to Present Preclinical and Clinical Data from its Mitochondrial Protonophore Portfolio at the American Diabetes Association’s 2026 Scientific Sessions OrsoBio, Inc. a clinical-stage biopharmaceutical company developing treatments for obesity and related metabolic disorders, announced new clinical and preclinical data…












